CYB704, Ocrevus-EU, Ocrevus-US — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-11 (month) in 3mo
ESTIMATED |
READOUT
Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab
Phase 3 · Relapsing Multiple Sclerosis |
Sandoz | CYB704, Ocrevus-EU, Ocrevus-US |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|